Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q2 2025 value amounting to 2332400.0%.

  • Barinthus Biotherapeutics' EBIT Margin changed N/A to 2332400.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 25987.38%, marking a year-over-year decrease of 255560400.0%. This contributed to the annual value of 454.07% for FY2024, which is 100090200.0% up from last year.
  • Barinthus Biotherapeutics' EBIT Margin amounted to 2332400.0% in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' EBIT Margin peaked at 1666800.0% during Q4 2021, and registered a low of 2332400.0% during Q2 2025.
  • Moreover, its 5-year median value for EBIT Margin was 2870.7% (2021), whereas its average is 58844.85%.
  • Per our database at Business Quant, Barinthus Biotherapeutics' EBIT Margin soared by 2000000000bps in 2021 and then tumbled by 2000000000bps in 2022.
  • Over the past 5 years, Barinthus Biotherapeutics' EBIT Margin (Quarter) stood at 1666800.0% in 2021, then plummeted by -100bps to 388.62% in 2022, then crashed by -1929bps to 7885.33% in 2023, then soared by 99bps to 62.66% in 2024, then crashed by -3722042bps to 2332400.0% in 2025.
  • Its EBIT Margin stands at 2332400.0% for Q2 2025, versus 6518.99% for Q1 2025 and 62.66% for Q3 2024.